Skip to main content
. 2021 May 24;22(1):556. doi: 10.3892/ol.2021.12817

Figure 5.

Figure 5.

Integrin α5/FAK-STAT3/AKT signaling pathway enhances icotinib resistance-associated malignancy. (A) Expression of proteins in the conventional pathway downstream of integrin in icotinib-resistant cells compared with parent cells. (B) Upregulated genes of resistant cells treated with or without icotinib in parent and resistant cells were analyzed using western blotting. (C) Western blotting of p-FAK, p-STAT3 and p-AKT in integrin α5-knockdown 827/IcoR and PC9/IcoR cells. *P<0.05 and **P<0.01. FAK, focal adhesion kinase; p-, phosphorylated; IcoR; icotinib-resistant; n.s., not significant.